Galenea license Organix 5-HT2C agonists

Galenea have licensed Organix’s 5-HT2C agonists for the treatment of obesity and other related disorders.

Green Cross pubish series of CB1 antagonists

Green Cross have published a series of biarylpyrazolyl oxadiazole based compounds as CB1 antagonists

Jenrin’s CB1 antagonists show efficacy with less adverse effects

Data presented at the Annual Scientific Meeting of the Obesity Society show Jenrin’s CB1 antagonist are capable of having a metabolic effect while reducing risks of psychiatric side effects.

Resolor (Prucalopride) safe and effective in Severe Chronic Constipation

Data presented at the United European Gastroenterology Week show Movetis’ Prucalopride to demonstrate efficacy and safety in patients with chronic constipation.

Pfizer publish series of Alpha1A Adrenoceptor Partial Agonists

Pfizer have published a series of 2-Imidazole Alpha1A Adrenoceptor Partial Agonists

J&J publish series of CCR2 antagonists

J&J have published a series of 7-Azaindole Piperidine CCR2 Antagonists

Daiichi Sankyo and Lilly continue talks with FDA re Prasugrel NDA

Daiichi Sankyo and Lilly are continuing to have discussions with the FDA regarding the review of the NDA for Prasugrel

Glenmark/Lilly suspend trials with TRPV1 antagonist GRC 6211 in OA

Glenmark and Lilly have announced they have suspended further clinical development for TRPV1 antagonist GRC 6211 in Osteoarthritis pain.

NeurogesX Submit NDA for NGX-4010 for Treatment of Postherpetic Neuralgia (PHN)

NeurogesX have submitted a new drug application (NDA) with the U.S. FDAS for NGX-4010 Dermal Capsaicin Patch for the management of pain due to postherpetic neuralgia (PHN).

Progenics and Ono to Codevelop Relistor in Japan

Ono have signed an agreement to license Relistor (methylnaltrexone bromide) from Progenics for development in Japan